Latanoprost Al (Latanoprost)

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

• Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
• Secondary open‑angle glaucoma: assists in pressure reduction when caused by other ocular disorders.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary muscle, activating a cascade that remodels extracellular matrix and increases uveoscleral outflow of aqueous humor. Enhanced outflow lowers intra‑ocular pressure, helping to control glaucoma and ocular hypertension.

Adverse reactions may occur with ocular prostaglandin therapy.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Eyelash changes: increased length, thickness, or darkness.
• Iris pigmentation: gradual darkening of the iris.
• Eye irritation: burning or stinging sensation.
• Blurred vision: transient visual disturbance.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Uveitis: inflammation of the uveal tract.
• Corneal edema: swelling of the cornea affecting clarity.
• Increased intra‑ocular pressure: paradoxical pressure rise.
• Ocular infection: risk of bacterial or fungal infection.
• Vision loss: rare but possible if complications arise.

Patients should be aware of specific safety considerations before using Latanoprost.

• Monitor intra‑ocular pressure: schedule regular eye examinations.
• Avoid use with active ocular infection: postpone treatment until resolved.
• Caution in history of uveitis: assess risk before initiation.
• Do not combine with other prostaglandin analogs without supervision: may cause excessive pressure lowering.
• Pregnancy and lactation: consult a physician before use.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analogs: risk of additive pressure‑lowering effect.
• Use with non‑steroidal anti‑inflammatory eye drops: may diminish therapeutic efficacy.
• Combination with systemic beta‑blockers: potential for enhanced hypotensive effects.

Moderate Interactions (Monitor Closely)

• Co‑administration with topical corticosteroids: may reduce drug absorption.
• Use with ocular anesthetics: monitor for increased irritation.
• Interaction with antihistamine eye drops: observe for altered intra‑ocular pressure response.